ストックスクリーナーアプリを入手
1.97
0.51%
0.01
前日終値:
$1.96
開ける：
$1.99
24時間の取引高:
617.34K
Relative Volume:
2.16
時価総額：
$118.02M
収益：
$8.38M
当期純損益:
$-27.19M
株価収益率:
-1.8073
EPS:
-1.09
ネットキャッシュフロー:
$-13.59M
1週間 パフォーマンス:
-2.48%
1か月 パフォーマンス:
+42.75%
6か月 パフォーマンス:
+178.05%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.93
$2.06
1週間の範囲:
$1.85
$2.1596
52週間の値動き範囲:
$0.65
$2.1596
Opus Genetics Inc Stock (IRD) Company Profile
IRD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
1.97 | 117.42M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.71 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.21 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.58 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-11 | 開始されました | Craig Hallum | Buy |
| 2024-11-13 | 再開されました | H.C. Wainwright | Buy |
Opus Genetics Inc (IRD) 最新ニュース
Is Opus Genetics Inc. (R3X1) stock at risk of policy regulationInsider Selling & Stepwise Trade Execution Plans - newser.com
Opus Genetics Inc. stock momentum explained2025 Winners & Losers & Safe Entry Momentum Tips - newser.com
Real time breakdown of Opus Genetics Inc. stock performanceJuly 2025 Highlights & Reliable Breakout Forecasts - newser.com
Applying chart zones and confluence areas to Opus Genetics Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Opus Genetics Inc. stock a safe haven assetWeekly Stock Recap & Consistent Growth Equity Picks - newser.com
Price action breakdown for Opus Genetics Inc.July 2025 Gainers & Weekly High Return Forecasts - newser.com
Can Opus Genetics Inc. stock maintain operating marginsJuly 2025 Sentiment & Stepwise Trade Execution Plans - newser.com
Does Opus Genetics Inc. stock trade at a discount to peers2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Can Opus Genetics Inc. stock hit analyst price targetsQuarterly Earnings Summary & Fast Exit and Entry Strategy Plans - newser.com
Opus Genetics (NASDAQ:IRD) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
How big funds are accumulating Opus Genetics Inc. (R3X1) stockJuly 2025 Sentiment & Low Drawdown Momentum Trade Ideas - newser.com
Can trapped investors hope for a rebound in Opus Genetics Inc.Earnings Performance Report & Risk Managed Investment Entry Signals - newser.com
What analysts say about Opus Genetics Inc R3X1 stockCapital Gains Strategies & Exceptional Profit Portfolio - earlytimes.in
Combining machine learning predictions for Opus Genetics Inc.Analyst Upgrade & Risk Adjusted Buy/Sell Alerts - newser.com
What data driven models say about Opus Genetics Inc.’s futureEarnings Overview Report & Stepwise Entry/Exit Trade Alerts - newser.com
Opus Genetics reports positive pediatric data from LCA5 gene therapy study - Eyes On Eyecare
Opus Genetics, Inc. (NASDAQ:IRD) Sees Large Increase in Short Interest - MarketBeat
How Opus Genetics Inc. (R3X1) stock performs in volatility spikesJuly 2025 Final Week & Weekly Setup with High ROI Potential - newser.com
Using R and stats models for Opus Genetics Inc. forecastingQuarterly Trade Review & High Accuracy Trade Alerts - newser.com
Opus Genetics Inc. stock daily chart insightsQuarterly Profit Review & Reliable Breakout Forecasts - newser.com
Opus Genetics (NASDAQ:IRD) Trading Up 4.4%Should You Buy? - MarketBeat
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 - GlobeNewswire
Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice - sharewise.com
Craig-Hallum Maintains Opus Genetics(IRD.US) With Buy Rating - 富途牛牛
What drives Opus Genetics Inc stock pricePrice Gap Trading Strategies & Capitalize On Fast Trends - earlytimes.in
H.C. Wainwright reiterates Buy rating on Opus Genetics stock, citing positive data - Investing.com Canada
Why pension funds invest in Opus Genetics Inc. (R3X1) stockWeekly Profit Analysis & Real-Time Sentiment Analysis - newser.com
H.C. Wainwright Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $6 - 富途牛牛
Opus Genetics Reports Positive Pediatric Data from - GlobeNewswire
Magnum Opus: Street drinks in LCA5 gene therapy phase I/II data - BioWorld MedTech
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) - GlobeNewswire
Opus Genetics Shares Encouraging Data From Inherited Retinal Degeneration Study - Nasdaq
Opus Genetics reports positive data from LCA5 gene therapy trial By Investing.com - Investing.com Australia
Opus Genetics reports positive data from LCA5 gene therapy trial - Investing.com India
Opus Genetics reports positive pediatric data from OPGx-LCA5 phase 1/2 trial in Leber congenital amaurosis type 5 (LCA5) - MarketScreener
Opus Genetics Inc (IRD) 財務データ
収益
当期純利益
現金流量
EPS
Opus Genetics Inc (IRD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| YERXA BENJAMIN R | President |
Nov 21 '24 |
Buy |
0.98 |
10,000 |
9,834 |
342,800 |
| Magrath George | Chief Executive Officer |
Nov 15 '24 |
Buy |
1.01 |
90,294 |
91,215 |
483,244 |
| Magrath George | Chief Executive Officer |
Nov 18 '24 |
Buy |
1.02 |
9,706 |
9,943 |
492,950 |
1.19%
大文字化:
|
ボリューム (24 時間):